Husted, S.

abciximab dalteparin patient cohort treatment dalteparin cohort bleeding placebo group trial heparin study syndrome 30 days ufh cohort infarction <0001 intervention heart /iiia eur heart j angina dalteparin substudy table platelet thrombocytopenia combination death outcome 7 days safety aspirin infusion stroke number inhibitor glycoprotein therapy baseline revascularization haemorrhage predictor event investigator troponin blood unfractionated heparin transfusion receptor randomized comparison abciximab treatment october cardiology addition gusto issue substudy difference artery elevation analysis gusto ivacs trial randomized treatment groups effect haemorrhage =intracranial haemorrhage abciximab 24 h event rate timi criteria regression analysis elsevier science ltd artery disease criteria haemoglobin st-segment elevation 48 h infusion abciximab groups european society c 5 g surgery